Hyperprogression with immunotherapy: Is it real?
File(s)Hyperprogression Editorial submitted_Rev1.docx (52.19 KB)
Accepted version
Author(s)
Popat, Sanjay
Type
Journal Article
Abstract
Hyperprogression on immune checkpoint inhibitor therapy has been previously described. This editorial reviews the phenomenon in the current context in light of findings reported by Yada Kanjanapan and her colleagues.
Date Issued
2019-04-15
Date Acceptance
2019-01-10
Citation
Cancer, 2019, 125 (8), pp.1218-1220
ISSN
0008-543X
Publisher
Wiley
Start Page
1218
End Page
1220
Journal / Book Title
Cancer
Volume
125
Issue
8
Copyright Statement
© 2019 American Cancer Society. This is the pre-peer reviewed version of the following article, which has been published in final form at https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.31997
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/30768797
Subjects
1112 Oncology And Carcinogenesis
Oncology & Carcinogenesis
Publication Status
Published
Coverage Spatial
United States
Date Publish Online
2019-02-15